Ender Kurt
Impact in
-
- Cancer Treatment and Pharmacology
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Emergency Medicine top 10%
- Hematological disorders and diagnostics
Papers in
- Oncology 14
- Cancer Treatment and Pharmacology 5
- Peptidase Inhibition and Analysis 2
- HER2/EGFR in Cancer Research 2
-
- Gastric Cancer Management and Outcomes 2
- Co-authors
- Türkkan Evrensel (33 shared papers)Osman Manavoğlu (17 shared papers)Özkan Kanat (21 shared papers)Mutlu Demiray (12 shared papers)Güzin Gönüllü (11 shared papers)Ömer Yerci (3 shared papers)Tülay Özçelik (1 shared paper)Hülya Öztürk (1 shared paper)
- Journals
- Cancer Investigation (2 papers)Medical Oncology (2 papers)Clinical & Translational Oncology (2 papers)Lung Cancer (1 paper)Cytokine (1 paper)
- Partner nations
- Türkiye
In The Last Decade
Ender Kurt
41 papers receiving 429 citations
Peers
Comparison fields: 5 of 68
- Oncology 205
- Emergency Medicine 43
- Cancer Research 57
- Chemical Health and Safety 2
- Hematology 29
Countries citing papers authored by Ender Kurt
This map shows the geographic impact of Ender Kurt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ender Kurt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ender Kurt more than expected).
Fields of papers citing papers by Ender Kurt
This network shows the impact of papers produced by Ender Kurt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ender Kurt. The network helps show where Ender Kurt may publish in the future.
Co-authors
The 25 scholars most cited alongside Ender Kurt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 98 | |
| 2 | 2003 | 38 | |
| 3 | 2005 | 27 | |
| 4 | 2003 | 23 | |
| 5 | 2003 | 21 | |
| 6 | 2012 | 21 | |
| 7 | Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. | 2015 | 16 |
| 8 | 2006 | 15 | |
| 9 | 2007 | 15 | |
| 10 | 2006 | 14 | |
| 11 | 2011 | 14 | |
| 12 | 2005 | 14 | |
| 13 | 2012 | 12 | |
| 14 | 2003 | 12 | |
| 15 | 2008 | 10 | |
| 16 | Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy. | 2015 | 9 |
| 17 | 2015 | 8 | |
| 18 | 2005 | 8 | |
| 19 | 2004 | 7 | |
| 20 | 2004 | 6 |
About Ender Kurt
Ender Kurt is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Pathology and Forensic Medicine and Dermatology, having authored 41 papers that have together received 448 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Gastric Cancer Management and Outcomes (2 papers), Peptidase Inhibition and Analysis (2 papers), HER2/EGFR in Cancer Research (2 papers), RNA modifications and cancer (2 papers), Mechanisms of cancer metastasis (2 papers), Chemotherapy-related skin toxicity (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). The work is most often cited by research in Oncology (205 citations), Emergency Medicine (43 citations), Cancer Research (57 citations), Chemical Health and Safety (2 citations) and Hematology (29 citations). Ender Kurt has collaborated with scholars based in Türkiye. Frequent co-authors include Türkkan Evrensel, Osman Manavoğlu, Özkan Kanat, Mutlu Demiray, Güzin Gönüllü, Ömer Yerci, Tülay Özçelik, Hülya Öztürk, Vildan Özkocaman and Fahir Özkalemkaş. Their work appears in journals such as Cancer Investigation, Medical Oncology, Clinical & Translational Oncology, Lung Cancer and Cytokine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.